Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Stopped Following the direction of the local (India) health authority, data specified in the protocol were not collected and study was cancelled.

Conditions

• HPV Infections

Interventions

• BIOLOGICAL: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Sponsor

Merck Sharp & Dohme LLC